for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sumitomo Dainippon Pharma Co Ltd

4506.T

Latest Trade

1,853.00JPY

Change

8.00(+0.43%)

Volume

325,300

Today's Range

1,847.00

 - 

1,874.00

52 Week Range

1,661.00

 - 

4,135.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Sumitomo Dainippon Pharma & Roivant Sciences Sign Definitive Agreement For Strategic Alliance

Oct 31 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUMITOMO DAINIPPON PHARMA AND ROIVANT SCIENCES SIGN DEFINITIVE AGREEMENT FOR STRATEGIC ALLIANCE.SUMITOMO DAINIPPON PHARMA CO LTD - ALLIANCE WILL INCLUDE ROIVANT'S OWNERSHIP INTERESTS IN MYOVANT, UROVANT, ENZYVANT, ALTAVANT, & SPIROVANT.SUMITOMO DAINIPPON PHARMA CO LTD - NEW COMPANY WILL BE LED BY CHIEF EXECUTIVE OFFICER MYRTLE POTTER.SUMITOMO DAINIPPON PHARMA CO LTD - ROIVANT WILL RECEIVE USD $3 BILLION FROM SUMITOMO DAINIPPON PHARMA AS A PAYMENT TO ENTER ALLIANCE.SUMITOMO DAINIPPON PHARMA CO LTD - PLANS TO PROVIDE FINANCIAL SUPPORT TO FIVE VANTS IN NEW COMPANY.SUMITOMO DAINIPPON PHARMA CO LTD - WILL ENTER SEPARATE STRATEGIC CLIENT RELATIONSHIPS WITH DATAVANT AND ALYVANT.

Sumitomo Dainippon Pharma Withdraws Offer To Acquire Australia's Cynata Therapeutics

Oct 17 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::WITHDRAWS OFFER TO ACQUIRE AUSTRALIA'S CYNATA THERAPEUTICS LIMITED <<<CYP.AX>>>.PARTIES HAVE BEEN UNABLE TO REACH AGREEMENT ON TERMS OF PROPOSED ACQUISITION.

Myovant Sciences' Founding Shareholder Roivant Sciences, And Sumitomo Dainippon Enter Into MOU

Sept 6 (Reuters) - Myovant Sciences Ltd <MYOV.N>: :MYOVANT SCIENCES' FOUNDING SHAREHOLDER ROIVANT SCIENCES, AND SUMITOMO DAINIPPON PHARMA ENTER INTO A MEMORANDUM OF UNDERSTANDING TO CREATE A BROAD STRATEGIC ALLIANCE.MYOVANT SCIENCES- ROIVANT'S OWNERSHIP INTEREST IN MYOVANT SCIENCES TO BE FULLY ASSUMED BY A NEW ENTITY, SUMITOMO DAINIPPON-ROIVANT ALLIANCE.SUMITOMO DAINIPPON-ROIVANT ALLIANCE EXPECTED TO CREATE NEW CORPORATE ENTITY WHICH WILL BE WHOLLY OWNED BY SUMITOMO DAINIPPON.MYOVANT SCIENCES IS ON-TRACK TO SUBMIT A NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION BY END OF THIS CALENDAR YEAR.NEW CORPORATE ENTITY, WHICH WILL BE WHOLLY OWNED BY SUMITOMO DAINIPPON, WILL ASSUME ROIVANT'S OWNERSHIP INTEREST IN MYOVANT SCIENCES.MYOVANT ALSO EXPECTS TO ANNOUNCE TOPLINE RESULTS FROM ITS PHASE 3 PROSTATE CANCER STUDY LATER THIS YEAR.ROIVANT AND SUMITOMO DAINIPPON HAVE STATED THAT THEY EXPECT TO SIGN DEFINITIVE AGREEMENT FOR ALLIANCE BY END OF OCT.

Sumitomo Dainippon Pharma And Roivant Sciences Enter Into MOU For Strategic Alliance

Sept 6 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUMITOMO DAINIPPON PHARMA CO LTD AND ROIVANT SCIENCES ENTER INTO A MEMORANDUM OF UNDERSTANDING FOR A STRATEGIC ALLIANCE.SUMITOMO DAINIPPON PHARMA - UNDER MOU SUMITOMO DAINIPPON PHARMA WILL ACQUIRE A CERTAIN AMOUNT (OVER 10%) OF ROIVANT’S SHARES.SUMITOMO DAINIPPON PHARMA - ROIVANT IS EXPECTED TO RECEIVE A TOTAL OF US$3 BILLION FROM SUMITOMO DAINIPPON PHARMA.SUMITOMO DAINIPPON PHARMA - FINANCIAL IMPACT OF POSSIBLE DEAL CURRENTLY UNDER REVIEW.

Cynata Therapeutics Receives Indicative Non-Binding Proposal From Sumitomo Dainippon Pharma

July 19 (Reuters) - Cynata Therapeutics Ltd <CYP.AX>::CONFIRMS RECEIPT OF INDICATIVE NON-BINDING PROPOSAL.DECIDED TO GRANT NON-EXCLUSIVE DUE DILIGENCE ACCESS TO SUMITOMO.DEAL FOR A$2.00 PER SHARE IN CASH.RECEIVED AN INDICATIVE, NON-BINDING AND CONDITIONAL PROPOSAL FROM SUMITOMO DAINIPPON PHARMA.CYNATA'S DISCUSSIONS WITH OTHER PARTIES HAVE CEASED.

Poxel And Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results For Imeglimin Phase 3 Trial (TIMES 3) In Japan

June 25 (Reuters) - POXEL SA <POXEL.PA>::POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE SECOND POSITIVE TOP-LINE RESULTS FOR IMEGLIMIN PHASE 3 TRIAL (TIMES 3) IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES.POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE SECOND POSITIVE TOP-LINE RESULTS FOR IMEGLIMIN PHASE 3 TRIAL (TIMES 3) IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES.PHASE 3 RESULTS FROM TIMES 2 AND 36-WEEK OPEN-LABEL EXTENSION PART OF TIMES 3 ARE ANTICIPATED AROUND END OF 2019.IMEGLIMIN JAPANESE NEW DRUG APPLICATION (JNDA) TARGETED FOR 2020.IMEGLIMIN IN COMBINATION WITH INSULIN PHASE 3 TIMES 3 16-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PART OF TRIAL MET ITS PRIMARY ENDPOINT.

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I

Oct 11(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.

FDA Issues CRL For New Drug Application For Dasotraline For The Treatment Of Adhd

Aug 31 (Reuters) - SUNOVION PHARMACEUTICALS ::FDA ISSUES A COMPLETE RESPONSE LETTER FOR NEW DRUG APPLICATION FOR DASOTRALINE FOR THE TREATMENT OF ADHD.SUNOVION PHARMACEUTICALS SAYS UPON COMPLETION OF REVIEW, FDA DETERMINED THEY CANNOT APPROVE DASOTRALINE NDA FOR TREATMENT OF ADHD IN CURRENT FORM.SUNOVION PHARMACEUTICALS SAYS PLANS TO MEET WITH FDA TO DISCUSS COMMENTS AND DETERMINE NEXT STEPS.SUNOVION PHARMACEUTICALS - FDA INDICATED ADDITIONAL DATA NEEDED TO FURTHER EVALUATE EFFICACY AND TOLERABILITY OF DASOTRALINE FOR TREATMENT OF ADHD.

Sumitomo Dainippon Pharma Signed A 5-Year Agreement To Provide Enterprise-Wide Access To Newest Solution In Scifinder Family, Scifinder

July 11 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::CAS - SUMITOMO DAINIPPON PHARMA SIGNED A 5-YEAR AGREEMENT TO PROVIDE ENTERPRISE-WIDE ACCESS TO NEWEST SOLUTION IN SCIFINDER FAMILY, SCIFINDER.

Carna Biosciences and Sumitomo Dainippon Pharma sign agreement on joint research, development, and commercialization of kinase inhibitors

March 27 (Reuters) - Carna Biosciences Inc <4572.T>:Says it and Sumitomo Dainippon Pharma Co Ltd <<<4506.T>>> , signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up